TBPH / Theravance Biopharma, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 25, 2025 THERAVANCE BIOPHARM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 25, 2025 THERAVANCE BIOPHARMA, INC.

Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy

Exhibit 99.1 Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy · Topline results anticipated in Q1 2026 and, if successful, planning for expedited NDA submission · If approved, ampreloxetine could address a critical unmet need as the first therapy with the potent

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 15, 2025 THERAVANCE BIOPHARM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 15, 2025 THERAVANCE BIOPHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third - party trademarks used h

Exhibit 99.2 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third - party trademarks used herein are the property of their respective owners. © 2025 Theravance Biopharma. All rights reserved. Theravance Biopharma Second Quarter

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 12, 2025 THERAVANCE BIOPHARM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 12, 2025 THERAVANCE BIOPHARMA, INC.

Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Exhibit 99.1 Theravance Biopharma, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update · YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1 · Pivotal Phase 3 CYPRESS study enrollment on track to complete by late summer · Completed sale of TRELEGY ELLIPTA royalty interest to GSK for $225 million · TRELEGY year-to-date

Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China’s NMPA

Exhibit 99.1 Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China’s NMPA · YUPELRI approved by China’s NMPA as the first once-daily nebulized LAMA for maintenance treatment of COPD · Approval triggers $7.5 million milestone payment from Viatris, with eligibility to receive further sales milestones and tiered royalties on net sales in China · Theravance Biopharma incurs no com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 10, 2025 THERAVANCE BIOPHARMA,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 10, 2025 THERAVANCE BIOPHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 5, 2025 THERAVANCE BIOPHARMA,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 5, 2025 THERAVANCE BIOPHARMA, INC.

Assignment Agreement, dated May 30, 2025, by and between Theravance Biopharma, Inc. and GlaxoSmithKline Intellectual Property Development Limited, a private company limited by shares registered under the laws of England and Wales, and, solely with respect to Section 16, Glaxo Group Limited, a private company limited by shares registered under the laws of England and Wales

Exhibit 2.1 ASSIGNMENT AGREEMENT This ASSIGNMENT AGREEMENT (the “Assignment Agreement”), effective as of May 30, 2025 (the “Effective Date”), is by and between Theravance Biopharma, Inc., a Cayman Islands exempted company (“Assignor”), GlaxoSmithKline Intellectual Property Development Limited, a private company limited by shares registered under the laws of England and Wales (“Assignee”), and, sol

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 30, 2025 THERAVANCE BIOPHARMA, INC.

Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

Exhibit 99.1 Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million · Definitive agreement to result in one-time $225 million cash payment · Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved · $225 m

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 19, 2025 THERAVANCE BIOPHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 8, 2025 THERAVANCE BIOPHARMA, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 8, 2025 THERAVANCE BIOPHARMA, INC.

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third - party trademarks used h

Exhibit 99.2 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third - party trademarks used herein are the property of their respective owners. © 2025 Theravance Biopharma. All rights reserved. Theravance Biopharma First Quarter 2

Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update

Exhibit 99.1 Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update · YUPELRI® (revefenacin) net sales of $58.3 million, recognized by Viatris, increased 6% versus Q1 20241 · TRELEGY net sales of $854M, as reported by GSK, increased 14% versus Q1 20242 · CYPRESS study open label enrollment nearing completion with final patient expected to be enrolled

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul

Theravance Biopharma, Inc. Executive Severance Plan and Summary Plan Description

Exhibit 10.19 THERAVANCE BIOPHARMA, INC. EXECUTIVE SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION (Originally effective June 2, 2014, as amended and restated effective November 13, 2024) The Theravance Biopharma, Inc. Executive Severance Plan (the “Plan”) is primarily designed to provide separation pay and other benefits to Theravance Biopharma, Inc. (the “Company”) executives who meet the eligibilit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36033

Subsidiaries of Theravance Biopharma, Inc.

Exhibit 21.1 Subsidiaries Theravance Biopharma US, LLC (Delaware) Theravance Biopharma Ireland Limited (Ireland) Theravance Biopharma R&D IP, LLC (Delaware) Theravance Biopharma Antibiotics IP, LLC (Delaware) Theravance Biopharma US Holdings, Inc. (Delaware) Triple Royalty Sub LLC (Delaware) Triple Royalty Sub II LLC (Delaware)

Theravance Biopharma, Inc. Insider Trading Policy and Guidelines with Respect to Certain Transactions in Securities

Exhibit 19 Theravance Biopharma, Inc. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Securities Effective as of October 30, 2024 TABLE OF CONTENTS Page INTRODUCTION 1 Legal prohibitions on insider trading 1 Detection and prosecution of insider trading 1 Penalties for violation of insider trading laws and this Policy 1 Compliance Officer 2 Reporting violations 2 Perso

Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results

Exhibit 99.1 Theravance Biopharma, Inc. Reports Record Fourth Quarter and Full Year 2024 Financial Results · YUPELRI® (revefenacin) US net sales, recognized by Viatris, reached an all-time high of $66.7 million in Q4 2024 and $238.6 million in FY 2024, up 10% and 8%, respectively, compared with 20231 · FY 2024 TRELEGY Net Sales, as reported by GSK, of $3.46 billion, up 26% compared with 2023 and t

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third - party trademarks used h

Exhibit 99.2 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third - party trademarks used herein are the property of their respective owners. © 2025 Theravance Biopharma. All rights reserved. Theravance Biopharma Fourth Quarter

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 26, 2025 THERAVANCE BIOPHARMA, INC.

TBPH / Theravance Biopharma, Inc. / Madison Avenue Partners, LP Passive Investment

SC 13G/A 1 theravance13ga4-11142024.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 4)* Theravance Biopharma, Inc. (Name of Issuer) Ordinary Shares, par value $0.00001 per share (Title of Class of Securities) G

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value

Exhibit 99.1 Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial Results and Announces Initiatives to Unlock Shareholder Value · Third quarter results highlight strong operational performance across key value drivers: o YUPELRI® (revefenacin) net sales of $62.2 million, recognized by Viatris, an all-time high, increased 7% versus Q3 2023 and 14% versus Q2 20241 o CYPRESS enrollment in-

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 12, 2024 THERAVANCE BIOPHARMA, INC.

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third - party trademarks used h

Exhibit 99.2 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third - party trademarks used herein are the property of their respective owners. © 2024 Theravance Biopharma. All rights reserved. Theravance Biopharma Third Quarter 2

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 18, 2024 THERAVANCE BIOPHARMA, INC.

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third - party trademarks used h

Exhibit 99.1 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third - party trademarks used herein are the property of their respective owners. © 2024 Theravance Biopharma. All rights reserved. Theravance Biopharma Investor Presen

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 10, 2024 THERAVANCE BIOPHARMA, INC.

TBPH / Theravance Biopharma, Inc. / BAUPOST GROUP LLC/MA - SC 13G/A Passive Investment

SC 13G/A 1 ef20035682sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 09 )* Theravance Biopharma, Inc (Name of Issuer) Common Stock (Title of Class of Securities) G8807B106 (CUSIP Number) August 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t

TBPH / Theravance Biopharma, Inc. / Newtyn Management, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* THERAVANCE BIOPHARMA, INC. (Name of Issuer) ORDINARY SHARE $0.00001 PAR VALUE (Title of Class of Securities) G8807B106 (CUSIP Number) August 7, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pu

TBPH / Theravance Biopharma, Inc. / BAUPOST GROUP LLC/MA - SC 13G/A Passive Investment

SC 13G/A 1 ef20033786sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 08 )* Theravance Biopharma, Inc (Name of Issuer) Common Stock (Title of Class of Securities) G8807B106 (CUSIP Number) July 31, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third - party trademarks used h

Exhibit 99.2 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third - party trademarks used herein are the property of their respective owners. © 2024 Theravance Biopharma. All rights reserved. Theravance Biopharma Second Quarter

Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update

Exhibit 99.1 Theravance Biopharma, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update · Q2 2024 YUPELRI® (revefenacin) net sales of $54.5 million, recognized by Viatris, decreased 1% from Q2 20231 · Viatris collaboration revenue of $14.3 million, increased 4% versus Q2 2023 · Partner Viatris submitted YUPELRI NDA in China; $7.5 million milestone if approved · Now expec

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 5, 2024 THERAVANCE BIOPHARMA, INC.

TBPH / Theravance Biopharma, Inc. / ODRE 2005 SLU - AMENDMENT NO. 1 Passive Investment

SC 13G/A 1 g610240sc13ga1.htm AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 – Exit Filing)* Theravance Biopharma, Inc. (Name of Issuer) Ordinary Shares (Title of Class of Securities) G8807B106 (CUSIP Number) May 10, 2024 (Date of Event Which Requires Filing of This Statement) Check the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Employment Contract with Aine Miller

Exhibit 10.3 [Theravance Biopharma Ireland Letterhead] 13 December 2019 STRICTLY PRIVATE & CONFIDENTIAL Aine Miller, PhD Re: Offer of Employment Dear Dr. Miller: On behalf of Theravance Biopharma Ireland Limited (the “Company”) I am pleased to offer you employment in the position of Vice President, Regulatory Affairs with the anticipated start date of 10 February 2020. It is a condition of this of

Separation and Release of Claims by and between Richard Graham and Theravance Biopharma US, Inc.

Exhibit 10.2 SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims (“Agreement”) is made and entered into by and between Richard Graham (“Employee”) and Theravance Biopharma US, Inc. (“Theravance” or “Company”). Employee and Theravance shall be referred to herein as the “Parties.” Employee’s employment with Theravance terminated on February 29, 2024 (the “Termi

Form of Restricted Share Purchase Agreement under the Amended and Restated 2013 Equity Incentive Plan

Exhibit 10.1 THERAVANCE BIOPHARMA INC. AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN RESTRICTED SHARE PURCHASE AGREEMENT THIS RESTRICTED SHARE PURCHASE AGREEMENT (the “Agreement”) is entered into as of [·], by THERAVANCE BIOPHARMA, INC., a Cayman Islands exempted limited liability company (the “Company”), and [·] (the “Purchaser”). SECTION 1. ACQUISITION OF SHARES. (a)Purchase of Ordinary Shares

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used her

Exhibit 99.2 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. First Quarter 2024 Financial Results and Business Update May 13 , 2024 © 2024 Theravance

Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update

Exhibit 99.1 Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update • Q1 2024 YUPELRI® (revefenacin) net sales of $55.2 million, recognized by Viatris, increased 18% from Q1 20231 • Viatris collaboration revenue of $14.5 million, increased 39% versus Q1 2023, reflecting margin improvement • Continued progress for ampreloxetine CYPRESS enrollment • Virt

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 13, 2024 THERAVANCE BIOPHARMA, INC.

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 8, 2024 THERAVANCE BIOPHARMA, INC.

TBPH / Theravance Biopharma, Inc. / Madison Avenue Partners, LP Passive Investment

SC 13G/A 1 theravance13ga-05032024.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 3)* Theravance Biopharma, Inc. (Name of Issuer) Ordinary Shares, par value $0.00001 per share (Title of Class of Securities) G8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul

TBPH / Theravance Biopharma, Inc. / Weiss Asset Management LP - SC 13D/A Activist Investment

SC 13D/A 1 d781829dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENT FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (AMENDMENT NO. 2)1 Theravance Biopharma, Inc. (Name of Issuer) Ordinary Shares (Title of Class of Securities) G8807B106 (CUSIP Number) Weiss Asset

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36033

Offer Letter with Rhonda Farnum dated July 9, 1018

Exhibit 10.39 June 12, 2018 REVISED OFFER Rhonda F. Farnum [ADDRESS] Dear Rhonda: Theravance Biopharma US, Inc. (the “Company” or “Theravance Biopharma US”) is pleased to offer you the exempt position of Vice President - Sales and Marketing - Senior Leadership Group, reporting to Frank Pasqualone. Your salary on an annualized basis will be $387,500. In addition, you will be paid a one-time employm

Theravance Biopharma, Inc. Policy for the Recovery of Erroneously Awarded Compensation

Exhibit 97.1 THERAVANCE BIOPHARMA, INC. POLICY FOR THE RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION 1. Purpose. The purpose of this Policy is to describe the circumstances in which Executive Officers will be required to repay or return Erroneously Awarded Compensation to members of the Company Group. This Policy is designed to comply with, and shall be interpreted to be consistent with, Section 10

Subsidiaries of Theravance Biopharma, Inc.

Exhibit 21.1 Subsidiaries Theravance Biopharma US, Inc. (Delaware) Theravance Biopharma UK Limited (England and Wales) Theravance Biopharma Ireland Limited (Ireland) Theravance Biopharma R&D IP, LLC (Delaware) Theravance Biopharma Antibiotics IP, LLC (Delaware) Theravance Biopharma US Holdings, Inc. (Delaware) Triple Royalty Sub LLC (Delaware) Triple Royalty Sub II LLC (Delaware)

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 28, 2024 THERAVANCE BIOPHARMA, INC.

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used her

Exhibit 99.2 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. Fourth Quarter & Full Year 2023 Financial Results and Business Update February 26 , 2024

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 26, 2024 THERAVANCE BIOPHARMA, INC.

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Exhibit 99.1 Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update · Q4 2023 YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 9% from Q4 2022, reaching an all-time high of $60.6 million1 · Full Year 2023 Viatris Collaboration Revenue increased 18% to $57.2 million · GAAP Net Loss of $8.5 million in Q4; Achieved goal of

TBPH / Theravance Biopharma, Inc. / Irenic Capital Management LP Passive Investment

SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Theravance Biopharma, Inc. (Name of Issuer) Ordinary Share $0.00001 Par Value (Title of Class of Securities) G8807B106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo

1. Joint Filing Agreement, dated as of February 14, 2024, by and between Irenic Capital Management LP, Irenic Capital Evergreen Master Fund LP, Adam Katz and Andrew Dodge.

EX-1 2 ex1.htm Exhibit 1 JOINT FILING AGREEMENT This Agreement will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on the date hereof with respect to the beneficial ownership by the undersigned of the ordinary shares of Theravance Biopharma, Inc. is being filed, and all amendments thereto will be filed, on behalf of each o

TBPH / Theravance Biopharma, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv02068-theravancebiopharmai.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 7)* Name of issuer: Theravance Biopharma Inc Title of Class of Securities: Common Stock CUSIP Number: G8807B106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 12, 2024 THERAVANCE BIOPHARMA, INC.

Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Exhibit 99.1 Theravance Biopharma Announces Results from the Phase 4 YUPELRI® PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD) DUBLIN– January 5, 2024 – Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced results from the Phase 4 PIFR-2 study of YUPELRI® (revefenacin) inhalation solution, the only once-daily, nebulized long-acting muscarinic an

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 5, 2024 THERAVANCE BIOPHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 26, 2023 THERAVANCE BIOPHA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 26, 2023 THERAVANCE BIOPHARMA, INC.

Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and Maximize Shareholder Value

Exhibit 99.1 Page 1 of 3 Theravance Biopharma, Inc. Announces Appointment of Jeremy Grant to Board of Directors Enters into Cooperation Agreement with Shareholder Irenic Capital Reaffirms Intention to Return All Excess Capital to Shareholders and Maximize Shareholder Value DUBLIN, December 21, 2023 – Theravance Biopharma, Inc. (“Theravance” or the “Company”) (NASDAQ: TBPH) today announced the appo

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 21, 2023 THERAVANCE BIOPHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Cooperation Agreement, dated as of December 21, 2023, by and among Theravance Biopharma, Inc., a Cayman Islands exempted company, Irenic Capital Management LP, a Delaware limited partnership, Irenic Capital Management GP LLC, a Delaware limited liability company, Irenic Capital Evergreen Master Fund LP, a Cayman Islands limited partnership, and Irenic Capital Evergreen Fund GP LLC, a Delaware limited liability company

Exhibit 10.1 Execution Version COOPERATION AGREEMENT This Cooperation Agreement (this “Agreement”), dated as of December 21, 2023 (the “Effective Date”), is by and among Irenic Capital Management LP, a Delaware limited partnership (“Irenic”), Irenic Capital Management GP LLC, a Delaware limited liability company, Irenic Capital Evergreen Master Fund LP, a Cayman Islands limited partnership, and Ir

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file numbe

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used her

Exhibit 99.2 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. Third Quarter 2023 Financial Results and Business Update November 7 , 2023 © 2023 Therav

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 7, 2023 THERAVANCE BIOPHARMA, INC.

Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update

Exhibit 99.1 Theravance Biopharma, Inc. Reports Third Quarter 2023 Financial Results and Provides Business Update · Q3 2023 YUPELRI® (revefenacin) net sales, recognized by Viatris, increased 9% from Q3 2022, reaching an all-time high of $58.3 million1 · Progress made towards the achievement of non-GAAP profitability, with Q3 2023 GAAP Net Loss of $9.0 million and Non-GAAP Loss of $0.7 million2 · C

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 27, 2023 THERAVANCE BIOPHAR

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): October 27, 2023 THERAVANCE BIOPHARMA, INC.

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used her

Exhibit 99.1 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. Investor Presentation September 2023 © 2023 Theravance Biopharma. All rights reserved. F

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 12, 2023 THERAVANCE BIOPH

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 12, 2023 THERAVANCE BIOPHARMA, INC.

TBPH / Theravance Biopharma Inc / Weiss Asset Management LP - SC 13D/A Activist Investment

SC 13D/A Page 1 of 4 Pages SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D/A (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENT FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (AMENDMENT NO. 1) Theravance Biopharma, Inc. (Name of Issuer) Ordinary Shares (Title of Class of Securities) G8807B106 (CUSIP Number) Weiss Asset Management L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 00

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used her

Exhibit 99.2 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. Second Quarter 2023 Financial Results and Business Update August 7 , 2023 © 2023 Therava

Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update

Exhibit 99.1 Theravance Biopharma, Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update ● Q2 2023 YUPELRI® (revefenacin) net sales of $55.0 million, recognized by Viatris, up 12% from Q2 20221 ● Q2 2023 YUPELRI total retail TRx and new to product TRx again reached all-time highs, up 26% and 53%, Y/Y, respectively2 ● PIFR-2 enrollment nearing completion; top-line data in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 7, 2023 THERAVANCE BIOPHARMA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 7, 2023 THERAVANCE BIOPHARMA, INC.

TBPH / Theravance Biopharma Inc / BAUPOST GROUP LLC/MA - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 07)* Theravance Biopharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) G8807B106 (CUSIP Number) June 30, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 9, 2023 THERAVANCE BIOPHARMA,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): June 9, 2023 THERAVANCE BIOPHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 0

Offer Letter with Aziz Sawaf dated June 16, 2014

Exhibit 10.2 [Theravance Biopharma Company Logo] June 16, 2014 Aziz Sawaf Dear Aziz: As you know, Theravance, Inc. (“Theravance”) recently spun-off its drug discovery and development business into a separate publicly traded company, Theravance Biopharma, Inc., a Cayman Islands corporation (the “Spin-Off”). You were offered a position with Theravance Biopharma US, Inc., (the “Company” or “Theravanc

Offer Letter with Brett Grimaud dated May 12, 2014

Exhibit 10.1 [Theravance Biopharma Company Logo] May 12, 2014 Brett Grimaud Dear Brett: As you know, Theravance, Inc. (“Theravance”) will spin-off its drug discovery and development business into a separate publicly traded company, Theravance Biopharma, Inc., a Cayman Islands corporation (the “Spin-Off’). You, together with substantially all of the current Theravance employees who are involved wit

Form of Notice of Restricted Share Unit Award

Exhibit 10.3 THERAVANCE BIOPHARMA, INC. 2013 EQUITY INCENTIVE PLAN NOTICE OF RESTRICTED SHARE UNIT AWARD You have been granted the number of restricted share units indicated below by Theravance Biopharma, Inc. (the “Company”) on the following terms: Name: «Name» Restricted Share Unit Award Details: Date of Grant: «DateGrant» Award Number: «AwardNumber» Restricted Share Units: «TotalShares» Each re

Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update

Exhibit 99.1 Theravance Biopharma, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update · Q1 2023 YUPELRI® (revefenacin) net sales of $47.0 million, recognized by Viatris, up 8% from Q1 20221 · Q1 2023 YUPELRI retail new patient starts and total prescriptions up 61% and 29%, respectively, year-over-year, reaching all-time highs2 · CYPRESS Phase 3 study of ampreloxetine re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 8, 2023 THERAVANCE BIOPHARMA, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 8, 2023 THERAVANCE BIOPHARMA, INC.

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used her

Exhibit 99.2 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. First Quarter 2023 Financial Results and Business Update May 8 , 2023 © 2023 Theravance

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 2, 2023 THERAVANCE BIOPHARMA, I

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 2, 2023 THERAVANCE BIOPHARMA, INC.

Amended and Restated Memorandum and Articles of Association

Exhibit 3.1 THE COMPANIES ACT (As Revised) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF Theravance biopharma, inc. Adopted by Special Resolution effective on MAY 2, 2023 1 THE COMPANIES ACT (As Revised) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF Theravance biopharma, inc. Adopte

Amended and Restated 2013 Equity Incentive Plan

Exhibit 10.1 AMENDED AND RESTATED 2013 EQUITY INCENTIVE PLAN THERAVANCE BIOPHARMA, INC. 2013 EQUITY INCENTIVE PLAN (ORIGINALLY ADOPTED EFFECTIVE OCTOBER 22, 2013, AMENDED & RESTATED EFFECTIVE FEBRUARY 14, 2023) 1 TABLE OF CONTENTS Page ARTICLE I INTRODUCTION 4 ARTICLE II ADMINISTRATION 4 2.1 General 4 2.2 Section 16 4 2.3 Powers of Administrator 4 2.4 Effect of Administrator’s Decisions 4 ARTICLE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 17, 2023 THERAVANCE BIOPHARMA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 17, 2023 THERAVANCE BIOPHARMA, INC.

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used her

Exhibit 99.1 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. 22 nd Annual Needham Virtual Healthcare Conference April 17 , 2023 © 2023 Theravance Bio

TBPH / Theravance Biopharma Inc / Weiss Asset Management LP - SC 13D Activist Investment

SC 13D CUSIP No. G8807B106 13D Page 1 of 8 Pages SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENT FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a) (AMENDMENT NO. )1 Theravance Biopharma, Inc. (Name of Issuer) Ordinary Shares (Title of Class of Securities) G8807B106 (CUSIP Number) Weis

JOINT FILING AGREEMENT

EX-99.1 CUSIP No. G8807B106 13D Page 8 of 8 Pages Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, Weiss Asset Management LP, BIP GP LLC, WAM GP LLC, and Andrew M. Weiss, hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13G and/or 13D (including any and all amendments thereto) with respect

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A 1 tm2312299d3defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 11, 2023 THERAVANCE BIOPHARMA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 11, 2023 THERAVANCE BIOPHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.     ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 13, 2023 THERAVANCE BIOPHARMA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): March 13, 2023 THERAVANCE BIOPHARMA, INC.

Subsidiaries of Theravance Biopharma, Inc.

Exhibit 21.1 Subsidiaries Theravance Biopharma US, Inc. (Delaware) Theravance Biopharma UK Limited (England and Wales) Theravance Biopharma Ireland Limited (Ireland) Theravance Biopharma R&D IP, LLC (Delaware) Theravance Biopharma Antibiotics IP, LLC (Delaware) Theravance Biopharma US Holdings, Inc. (Delaware) Triple Royalty Sub LLC (Delaware) Triple Royalty Sub II LLC (Delaware)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No. 1) Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 9, 202

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.

Settlement Agreement and Release of Claims by and between Andrew Hindman and Theravance Biopharma US, Inc., dated January 10, 2023

Exhibit 10.77 SEPARATION AGREEMENT AND RELEASE OF CLAIMS This Separation Agreement and Release of Claims (“Agreement”) is made and entered into by and between Andrew Hindman (“Employee”) and Theravance Biopharma US, Inc. (“Theravance” or “Company”). Employee and Theravance shall be referred to herein as the “Parties.” Employee’s employment with Theravance terminated on December 31, 2022 (the “Term

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36033

Audited financial statements of Theravance Respiratory Company, LLC for the year ended December 31, 2021

Exhibit 10.72 Theravance Respiratory Company, LLC Financial Statements as of and for the Two Years Ended December 31, 2021 and December 31, 2020, and Report of Independent Registered Public Accounting Firm 1 THERAVANCE RESPIRATORY COMPANY, LLC. INDEX TO FINANCIAL STATEMENTS Report of Independent Registered Public Accounting Firm (PCAOB ID 248) 3 Financial Statements: Balance Sheets as of December

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

DEFA14A 1 tm238017d2defa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (a

Continued Transformation Positions Theravance Biopharma for Value Creation • The Board and management team regularly evaluate opportunities to enhance shareholder value and are committed to acting in the best interests of Theravance Biopharma (the "

Exhibit 99.1 Continued Transformation Positions Theravance Biopharma for Value Creation • The Board and management team regularly evaluate opportunities to enhance shareholder value and are committed to acting in the best interests of Theravance Biopharma (the " Company ") and its shareholders • Announced significant cost reduction program in September 2021 to reduce headcount by ~75% and as a res

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 28, 2023 THERAVANCE BIOPHA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 28, 2023 THERAVANCE BIOPHARMA, INC.

Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update

Exhibit 99.1 Theravance Biopharma, Inc. Announces Strategic Actions and Reports Fourth Quarter / Full Year 2022 Financial Results and Business Update · Increases capital return program to $325 million from $250 million; as of 2/27/23, approximately $170 million remains in the program · Discontinuing investments in research, reducing headcount by approximately 17% · Reports highest quarter of YUPEL

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 26, 2023 THERAVANCE BIOPHARMA, INC.

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used her

Exhibit 99.2 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. Strategic Actions and Fourth Quarter / Full Year 2022 Financial Results and Business Upd

JOINT FILING AGREEMENT

EX-99 2 ss1758628ex99a.htm JOINT FILING AGREEMENT EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated December 31, 2022 (the “Schedule 13G”), with respect to the Ordinary Share $0.00001 Par Value, of Theravance Biopharma, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securit

TBPH / Theravance Biopharma Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Passive Investment

SC 13G/A 1 ss1758628sc13ga.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No. 2)* Under the Securities Exchange Act of 1934 Theravance Biopharma, Inc. (Name of Issuer) Ordinary Share $0.00001 Par Value (Title of Class of Securities) G8807B106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) C

TBPH / Theravance Biopharma Inc / Madison Avenue Partners, LP Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 2)* Theravance Biopharma, Inc. (Name of Issuer) Ordinary Shares, par value $0.00001 per share (Title of Class of Securities) G8807B106 (CUSIP Number) December 31, 202

TBPH / Theravance Biopharma Inc / BAUPOST GROUP LLC/MA - NONE Passive Investment

SC 13G/A 1 doc1.htm NONE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 06)* Theravance Biopharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) G8807B106 (CUSIP Number) Calendar Year 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t

TBPH / Theravance Biopharma Inc / Weiss Asset Management LP Passive Investment

SC 13G/A 1 tbph13ga31dec2022.htm CUSIP NO. G8807B106 SCHEDULE 13G/A PAGE 1 OF 10 PAGES =============================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* THERAVANCE BIOPHARMA, INC. - (Name of Issuer) Ordinary Share $0.00001 Par Value - (Ti

TBPH / Theravance Biopharma Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv02037-theravancebiopharmai.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 6)* Name of issuer: Theravance Biopharma Inc. Title of Class of Securities: Common Stock CUSIP Number: G8807B106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box

Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets

EX-99.1 2 tm232391d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Theravance Biopharma, Inc. Highlights 2022 Accomplishments and 2023 Key Targets • Strategic priorities focused on continued Net Sales growth for YUPELRI® (revefenacin) and conduct of the ampreloxetine Phase 3 study (CYPRESS) in Multiple System Atrophy (MSA) patients with symptomatic neurogenic orthostatic hypotension (nOH) • Initiate CYPRESS

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 9, 2023 THERAVANCE BIOPHARM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 9, 2023 THERAVANCE BIOPHARMA, INC.

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used her

Exhibit 99.2 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. Theravance Biopharma Investor Presentation January 2023 © 2023 Theravance Biopharma. All

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 9, 2022 THERAVANCE BIOPHARMA, INC.

Press Release dated November 22, 2022.

Exhibit (a)(5)(v) Theravance Biopharma, Inc. Announces Final Results of Tender Offer DUBLIN, IRELAND – NOVEMBER 22, 2022 – Theravance Biopharma, Inc. (“Theravance Biopharma” or the “Company”) (NASDAQ: TBPH) today announced the final results of its Dutch auction tender offer (the “Offer”) to purchase up to $95 million of its ordinary shares, par value $0.00001 per share (the “Shares”), which expire

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 5) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 5) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Filing Person (as Offeror)) ORDINARY SHARES, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) G8807B106 (CUSIP Number of Class of Securitie

Press Release dated November 18, 2022.

Exhibit (a)(5)(iv) Theravance Biopharma, Inc. Announces Preliminary Results of Tender Offer DUBLIN, IRELAND ? NOVEMBER 18, 2022 ? Theravance Biopharma, Inc. (?Theravance Biopharma? or the ?Company?) (NASDAQ: TBPH) today announced the preliminary results of its Dutch auction tender offer (the ?Offer?) to purchase up to $95 million of its ordinary shares, par value $0.00001 per share (the ?Shares?),

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 4) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 4) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Filing Person (as Offeror)) ORDINARY SHARES, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) G8807B106 (CUSIP Number of Class of Securitie

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 3) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 3) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Filing Person (as Offeror)) ORDINARY SHARES, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) G8807B106 (CUSIP Number of Class of Securitie

THERAVANCE BIOPHARMA, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Exhibit 99.1 THERAVANCE BIOPHARMA, INC. UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS On July 20, 2022, Theravance Biopharma, Inc. (the ?Company?) completed the sale of its 2,125 Class B Units and 6,375 Class C Units (collectively, the ?Issuer II Units?) of Theravance Respiratory Company, LLC (?TRC?) to Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management ve

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

First Amendment to the Theravance Biopharma, Inc. Change in Control Severance Plan

Exhibit 10.4 ? Execution Version ? FIRST AMENDMENT TO THE THERAVANCE BIOPHARMA, INC. CHANGE IN CONTROL SEVERANCE PLAN ? The following amendment (the ?First Amendment?) to the Theravance Biopharma, Inc. (the ?Company?) Change in Control Severance Plan (the ?Plan?) was adopted by the Board of Directors of the Company (the ?Board?) on July 12, 2022. Capitalized terms used and not otherwise defined he

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 2) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 2) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Filing Person (as Offeror)) ORDINARY SHARES, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) G8807B106 (CUSIP Number of Class of Securitie

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 7, 2022 THERAVANCE BIOPHARMA, INC.

Press Release dated November 7, 2022.

Exhibit (a)(5)(iii) Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer ? Reported another record quarter of YUPELRI? (revefenacin) net sales and profitability: $18.7 million Q3 2022 sales up 35% from Q3 2021 (TBPH implied 35% share)1 ? Presented ampreloxetine data in neurogenic orthostatic hypotension (nOH) at the 33rd Interna

Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer

Exhibit 99.1 Theravance Biopharma, Inc. Reports Third Quarter 2022 Financial Results, Provides Business Update and Extends Tender Offer ? Reported another record quarter of YUPELRI? (revefenacin) net sales and profitability: $18.7 million Q3 2022 sales up 35% from Q3 2021 (TBPH implied 35% share)1 ? Presented ampreloxetine data in neurogenic orthostatic hypotension (nOH) at the 33rd International

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and

SC TO-I/A 1 tm2229804d1sctoi.htm SC TO-I/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Filing Person (as Offeror)) ORDINARY SHARES, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) G8

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used her

Exhibit 99.2 THERAVANCE BIOPHARMA ? , THERAVANCE ? , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ? are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. Third Quarter 2022 Financial Results and Business Update November 7, 2022 ? 2022 Therava

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used her

Exhibit 99.2 THERAVANCE BIOPHARMA ? , THERAVANCE ? , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ? are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. Ampreloxetine Data in Neurogenic Orthostatic Hypotension Presented at the 33 rd Internat

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 2, 2022 THERAVANCE BIOPHARMA, INC.

Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System

Exhibit 99.1 Ampreloxetine Data in Neurogenic Orthostatic Hypotension to be Presented at the 33rd International Symposium on the Autonomic Nervous System ? Totality of Evidence from the Phase 3 Clinical Program Demonstrates Ampreloxetine was Effective in Treating Symptoms and Improving Activities of Daily Living in MSA Patients with Neurogenic Orthostatic Hypotension ? Safety Profile of Ampreloxet

[Remainder of page intentionally left blank.]

October 6, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F.

Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

? ?Exhibit (a)(1)(iv)? Offer to Purchase Ordinary Shares (CUSIP No. G8807B106) Of Theravance Biopharma, Inc. For An Aggregate Cash Purchase Price of Up to $95 Million At a Purchase Price Not Greater than $10.50 Nor Less Than $9.75 Per Share ? ? THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT MIDNIGHT, NEW YORK CITY TIME, AT THE END OF THE DAY ON NOVEMBER 10, 2022, UNLESS THE OFFER

Notice of Guaranteed Delivery.

? ?Exhibit (a)(1)(iii)? NOTICE OF GUARANTEED DELIVERY (Not to be used for Signature Guarantee) THERAVANCE BIOPHARMA, INC.

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Schedule TO (Form Type) Theravance Biopharma, Inc.

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Filing Person (as

? ? ? SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ? THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Filing Person (as Offeror)) ? ORDINARY SHARES, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) G8807B106 (CUSIP Number of Class of Securities) Bre

Letter of Transmittal dated September 28, 2022.

? ?Exhibit (a)(1)(ii)? LETTER OF TRANSMITTAL To Tender Ordinary Shares (CUSIP Number G8807B106 ) of THERAVANCE BIOPHARMA, INC.

Form of Summary Advertisement as published on September 28, 2022.

Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell ordinary shares of Theravance Biopharma, Inc.

Offer to Purchase dated September 28, 2022.

TABLE OF CONTENTS ?Exhibit (a)(1)(i)? Offer to Purchase Ordinary Shares (CUSIP No.

Share Repurchase Agreement dated September 16, 2022, by and between Theravance Biopharma, Inc. and GSK Finance (No.3) plc.

Exhibit (d)(8) EXECUTION COPY SHARE REPURCHASE AGREEMENT THIS SHARE REPURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of September 16, 2022, by and between Theravance Biopharma, Inc.

Press Release dated September 28, 2022.

Exhibit (a)(5)(ii) Theravance Biopharma Announces Tender Offer For Up To $95 Million Of Its Ordinary Shares DUBLIN ? September 28, 2022 ? Theravance Biopharma, Inc.

Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees.

? ?Exhibit (a)(1)(v)? Offer to Purchase Ordinary Shares (CUSIP No. G8807B106) Of Theravance Biopharma, Inc. For An Aggregate Cash Purchase Price of Up to $95 Million At a Purchase Price Not Greater than $10.50 Nor Less Than $9.75 Per Share ? ? THE OFFER, PRORATION PERIOD AND WITHDRAWAL RIGHTS WILL EXPIRE AT MIDNIGHT, NEW YORK CITY TIME, AT THE END OF THE DAY ON NOVEMBER 10, 2022, UNLESS THE OFFER

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 20, 2022 THERAVANCE BIOPHARMA, INC.

Share Repurchase Agreement by and between the Notes Issuer and Theravance Biopharma dated as of September 16, 2022

GSK plc SC 13D/A Exhibit 12 EXECUTION COPY SHARE REPURCHASE AGREEMENT THIS SHARE REPURCHASE AGREEMENT (this ?Agreement?) is made and entered into as of September 16, 2022, by and between Theravance Biopharma, Inc.

TBPH / Theravance Biopharma Inc / GLAXOSMITHKLINE PLC - AMENDMENT TO FORM SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 10)* THERAVANCE BIOPHARMA, INC. (Name of Issuer) Ordinary Shares, par value, $0.00001 (Title of Class of Securities) G8807B106 (CU

Press Release dated September 19, 2022 (filed as Exhibit 99.1 to the Company’s Schedule TO-C, filed on September 19, 2022 and incorporated by reference).

Exhibit 99.1 Theravance Biopharma, Inc. Initiates $250 Million Capital Return Program ? The Company has agreed to purchase GSK?s entire holdings at $9.75 per share ? The Company plans to launch a Dutch auction tender offer in the near term to purchase approximately $95 million of its ordinary shares ? The Company plans to enter into an Open Market Share Repurchase Plan subsequent to the tender off

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 16, 2022 THERAVANCE BIOPHARMA, INC.

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Filing Person (as

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Filing Person (as Offeror)) ORDINARY SHARES, PAR VALUE $0.00001 PER SHARE (Title of Class of Securities) G8807B106 (CUSIP Number of Class of Securities) Brett Grimaud G

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 13, 2022 THERAVANCE BIOPHARMA, INC.

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used her

Exhibit 99.1 THERAVANCE BIOPHARMA ? , THERAVANCE ? , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ? are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. Transformed and Focused on Medicines that Make a Difference ? September 12, 2022 ? 2022

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 3) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 3) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Filing Person (as Offeror)) 3.25% CONVERTIBLE SENIOR NOTES DUE 2023 (Title of Class of Securities) 88339K AA0 (CUSIP Number of Class of Securities) Br

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 25, 2022 THERAVANCE BIOPHARMA, INC.

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 2) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 2) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Filing Person (as Offeror)) 3.25% CONVERTIBLE SENIOR NOTES DUE 2023 (Title of Class of Securities) 88339K AA0 (CUSIP Number of Class of Securities) Br

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

[Remainder of page intentionally left blank.]

CORRESP 1 filename1.htm August 5, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F. Street, N.E. Washington, D.C. 20549 Attention: Christina Chalk Re: Theravance Biopharma, Inc. Schedule TO-I filed July 26, 2022 File No. 5-88552 Ladies and Gentlemen: On behalf of Theravance Biopharma, Inc. (the “Company”), this letter responds to the comments se

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO (Amendment No. 1) TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Filing Person (as Offeror)) 3.25% CONVERTIBLE SENIOR NOTES DUE 2023 (Title of Class of Securities) 88339K AA0 (CUSIP Number of Class of Securities) Br

Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Exhibit 99.1 Theravance Biopharma, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update ? Highest quarter of YUPELRI? (revefenacin) net sales and profitability to date1: $17.2M Q2 2022 sales up 17% from Q2 2021 (implied 35% share) ? Ampreloxetine discussions with FDA create a path to NDA filing with one additional Phase 3 clinical study in Multiple System Atrophy (MSA) p

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 4, 2022 THERAVANCE BIOPHARMA, INC.

Second Quarter 2022 Financial Results and Business Update August 4, 2022 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in t

Exhibit 99.2 Second Quarter 2022 Financial Results and Business Update August 4, 2022 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. © 2022 Theravan

TBPH / Theravance Biopharma Inc / GLAXOSMITHKLINE PLC - AMENDMENT TO FORM SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 9)* THERAVANCE BIOPHARMA, INC. (Name of Issuer) Ordinary Shares, par value, $0.00001 (Title of Class of Securities) G8807B106 (CUS

Press Release dated July 26, 2022.

Exhibit (a)(5)(i) Theravance Biopharma Announces Tender Offer For Outstanding 3.25% Convertible Senior Notes Due 2023 DUBLIN ? July 26, 2022 ? Theravance Biopharma, Inc. (?Theravance Biopharma? or the ?Company?) (NASDAQ: TBPH) today announced a tender offer (the ?Offer?) to purchase any and all of its outstanding 3.25% Convertible Senior Notes due 2023 (the ?Convertible Notes?). As of July 26, 202

Offer to Purchase, dated July 26, 2022, (filed as Exhibit (a)(1)(i) to the Company’s Schedule TO on July 26, 2022 and incorporated by reference).

TABLE OF CONTENTS ?Exhibit (a)(1)(i)? OFFER TO PURCHASE Theravance Biopharma, Inc.

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Schedule TO (Form Type) Theravance Biopharma, Inc.

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Filing Person (as

? ? ? SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ? SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) or 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 ? THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Filing Person (as Offeror)) ? 3.25% CONVERTIBLE SENIOR NOTES DUE 2023 (Title of Class of Securities) 88339K AA0 (CUSIP Number of Class of Securities) Brett Gr

Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 20, 2022 THERAVANCE BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-36033 98-1226638 (State or Other Jurisdiction of (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Fili

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 THERAVANCE BIOPHARMA, INC. (Name of Subject Company (Issuer) and Filing Person (Offeror)) 3.25% CONVERTIBLE SENIOR NOTES DUE 2023 (Title of Class of Securities) 88339K AA0 (CUSIP Number of Class of Securities) Brett Gri

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 13, 2022 THERAVANCE BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-36033 98-1226638 (State or Other Jurisdiction of (Commission File Nu

Equity Purchase and Funding Agreement, dated as of July 13, 2022, by and between Theravance Biopharma, Inc. and Royalty Pharma Investments 2019 ICAV

Exhibit 2.1 ? EQUITY PURCHASE AND FUNDING AGREEMENT ? BY AND BETWEEN ? THERAVANCE BIOPHARMA,?INC. ? AND ? ROYALTY PHARMA INVESTMENTS 2019 ICAV ? JULY 13, 2022 ? ? ? ? TABLE OF CONTENTS ? Page ? Section?1 ? DEFINED TERMS; RULES OF CONSTRUCTION ? 1.1 Defined Terms 2 1.2 Other Terms 14 1.3 Rules?of Construction 14 ? ? ? Section?2 ? PURCHASE AND SALE OF EQUITY ? 2.1 Purchase and Sale of Equity; Amprel

Release Agreement, dated as of July 13, 2022, by and among Innoviva, Inc., Innoviva TRC Holdings LLC, Royalty Pharma Investments 2019 ICAV, Theravance Respiratory Company, LLC, Theravance Biopharma, Inc., Theravance Biopharma US Holdings, Inc. and Triple Royalty Sub II LLC

Exhibit 10.2 RELEASE AGREEMENT This Release Agreement (?Agreement?) is made as of July 13, 2022 by and among (i) Innoviva, Inc., a Delaware corporation (?Innoviva?), (ii) Innoviva TRC Holdings LLC, a Delaware limited liability company (?Innoviva Seller?), (iii) Royalty Pharma Investments 2019 ICAV, an Irish collective asset-management vehicle (the ?Purchaser?), (iv) Theravance Respiratory Company,

Master Consent, dated as of July 13, 2022, by and among Glaxo Group Limited, Theravance Biopharma, Inc. and Royalty Pharma Investments 2019 ICAV

Exhibit 10.1 ? CONFIDENTIAL ? MASTER CONSENT ? This Master Consent (this ?Agreement?) is entered into as of July?13, 2022 by and among (i)?Glaxo Group Limited, a private company limited by shares registered under the laws of England and Wales (?GSK?), (ii)?Theravance Biopharma,?Inc., a Cayman Islands exempted company (?Theravance Biopharma?), and (iii)?Royalty Pharma Investments 2019 ICAV, an Iris

Transcript of Investor Presentation on July 13, 2022.

Exhibit 99.1 Theravance Biopharma (IR Call) July 13, 2022 Corporate Speakers: ? Gail Cohen; Theravance Biopharma; Corporate Communications & IR ? Rick Winningham; Theravance Biopharma; CEO ? Andrew Hindman; Theravance Biopharma; CFO Participants: ? David Risinger; SVB Securities; Analyst ? Liisa Bayko; Evercore ISI; Analyst ? Douglas Taso; HC Wainwright; Analyst ? Joseph Stringer; Needham & Compan

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 13, 2022 THERAVANCE BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-36033 98-1226638 (State or Other Jurisdiction of (Commission File Nu

Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value

Exhibit 99.1 Theravance Biopharma to Sell TRELEGY ELLIPTA Royalty Interests to Royalty Pharma for Approximately $1.1 Billion in Upfront Cash with Over $1.5 Billion in Potential Total Value ? Over $1.5 Billion in Potential Total Value, Including Approximately $1.1 Billion in Upfront Cash, up to $250 Million in Sales-Based Milestone Payments and an Estimated NPV Approximately $200 Million of Rights

Strategic Transaction Between Theravance Biopharma and Royalty Pharma July 13, 2022 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of comp

Exhibit 99.2 Strategic Transaction Between Theravance Biopharma and Royalty Pharma July 13, 2022 THERAVANCE BIOPHARMA ? , THERAVANCE ? , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ? are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. ? 20

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 13, 2022 THERAVANCE BIOPHARM

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): July 13, 2022 THERAVANCE BIOPHARMA, INC. (Exact Name of Registrant as Specified in its Charter) Cayman Islands 001-36033 98-1226638 (State or Other Jurisdiction of (Commission File Nu

TBPH / Theravance Biopharma Inc / Weiss Asset Management LP Passive Investment

CUSIP NO. G8807B106 SCHEDULE 13G PAGE 1 OF 10 PAGES =============================================================================== UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* THERAVANCE BIOPHARMA, INC. - (Name of Issuer) Ordinary Share $0.00001 Par Value - (Title of Class of Securities) G8807B106 -

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): May 5, 2022 THERAVANCE BIOPHARMA, INC.

First Quarter 2022 Financial Results and Business Update May 5, 2022 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U

Exhibit 99.2 First Quarter 2022 Financial Results and Business Update May 5, 2022 THERAVANCE BIOPHARMA ? , THERAVANCE ? , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ? are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. ? 2022 Theravance B

Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Exhibit 99.1 Theravance Biopharma, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update ? Implied 35% share of YUPELRI? (revefenacin) net sales1: $15.3M Q1 2022 up 19% from Q1 2021 ? TRELEGY Q1 2022 global net sales: $454M, up 33% from Q1 20212 ? Results from a Phase 3 study of ampreloxetine showed a benefit in study patients with multiple system atrophy (MSA) ? Restructu

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 26, 2022 THERAVANCE BIOPHARMA, INC.

TBPH / Theravance Biopharma Inc / ODRE 2005 SLU - SC 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Theravance Biopharma, Inc. (Name of Issuer) Ordinary Shares (Title of Class of Securities) G8807B106 (CUSIP Number) March 18, 2022 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which th

Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): April 4, 2022 THERAVANCE BIOPHARMA, INC.

© Theravance Biopharma (Unpublished Work). All rights reserved. THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. a

Exhibit 99.2 ? Theravance Biopharma (Unpublished Work). All rights reserved. THERAVANCE BIOPHARMA ? , THERAVANCE ? , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ? are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third - party trademarks used herein are the property of their respective owners. Study 0170 (REDWOOD) A

Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH)

Exhibit 99.1 Theravance Biopharma, Inc. Announces Results from Study 0170, a Second Phase 3 Study of Ampreloxetine, in Patients with Symptomatic Neurogenic Orthostatic Hypotension (nOH) ? Results from Study 0170 show a benefit in study patients with multiple system atrophy (MSA) ? Company beginning discussions with potential strategic partners and planning health authority interactions to expedite

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   )

DEF 14A 1 tm223406-1def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.   ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-8 Theravance Biopharma, Inc. Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, $0.00001 par value 457 (h) 3,428,571 (3) $ 10.18 $ 34,902,853 0.0000927 $ 3,235.49 Equity Ordinary Share

As filed with the Securities and Exchange Commission on March 4, 2022

As filed with the Securities and Exchange Commission on March 4, 2022 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Consulting Agreement between Vijay Sabesan and Theravance Biopharma US, Inc., dated November 30, 2021

Exhibit 10.70 ? CONSULTING AGREEMENT Effective November 30, 2021 (the ?Effective Date?), Vijay Sabesan (?Consultant?) and Theravance Biopharma US, Inc. (?Theravance Biopharma? or the ?Company?) agree as follows: 1.Services and Payment. Consultant agrees to consult with and advise Theravance Biopharma from time to time, at Theravance Biopharma?s request and as reasonably agreed to by the parties (?

Audited financial statements of Theravance Respiratory Company, LLC for the year ended December 31, 2021

Exhibit 10.72 ? Theravance Respiratory Company, LLC ? Financial Statements as of and for the Three Years Ended December 31, 2021 and Report of Independent Registered Public Accounting Firm ? ? 1 THERAVANCE RESPIRATORY COMPANY, LLC. INDEX TO FINANCIAL STATEMENTS ? ? ? Report of Independent Registered Public Accounting Firm (PCAOB ID 248) 3 ? ? Financial Statements: ? Balance Sheets as of December 3

Subsidiaries of Theravance Biopharma, Inc.

Exhibit 21.1 ? Subsidiaries ? Theravance Biopharma US, Inc. (Delaware) Theravance Biopharma UK Limited (England and Wales) Theravance Biopharma Ireland Limited (Ireland) Theravance Biopharma R&D IP, LLC (Delaware) Theravance Biopharma Antibiotics IP, LLC (Delaware) Theravance Biopharma US Holdings, Inc. (Delaware) Triple Royalty Sub LLC (Delaware) Triple Royalty Sub II LLC (Delaware) ?

Settlement Agreement by and between Ann Brady and Theravance Biopharma Ireland Limited, dated November 2, 2021

? Exhibit 10.71 EXECUTION COPY SETTLEMENT AGREEMENT THIS AGREEMENT is made BETWEEN: THERAVANCE BIOPHARMA IRELAND LIMITED whose registered office is at Connaught House, 1 Burlington Road, Dublin 4, D04 C5Y6 (the ?Company?, which expression shall, where the context so permits or requires, include any Group Company (as defined below); and ANN BRADY (the ?Employee?), together the ?Parties? and each a

Form of Separation Agreement and Release of Claims between California-based departing executives and Theravance Biopharma US, Inc.

Exhibit 10.69 ? SEPARATION AGREEMENT AND RELEASE OF CLAIMS ? This Separation Agreement and Release of Claims (?Agreement?) is made and entered into by and between [] (?Employee?) and Theravance Biopharma US, Inc. (?Theravance? or ?Company?). Employee and Theravance shall be referred to herein as the ?Parties.? ? Employee?s employment with Theravance terminated on November 30, 2021 (the ?Terminatio

Fourth Quarter and Full Year 2021 Financial Results and Business Update February 23, 2022 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group o

Exhibit 99.2 Fourth Quarter and Full Year 2021 Financial Results and Business Update February 23, 2022 THERAVANCE BIOPHARMA ? , THERAVANCE ? , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ? are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): February 23, 2022 THERAVANCE BIOPHARMA, INC.

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Exhibit 99.1 Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update ? Implied 35% share of YUPELRI? (revefenacin) net sales1: $15.3M Q4 2021 up 13% from Q4 2020, $56.7M FY 2021 up 13% from FY 2020 ? TRELEGY Q4 2021 global net sales: $479M, up 52% from Q4 2020, $1,674M FY 20212 up 58% from FY 2020 ? Continued execution of cost-cutting ini

TBPH / Theravance Biopharma Inc / Point72 Asset Management, L.P. - SCHEDULE 13G (AMENDMENT NO. 1) Passive Investment

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* (Name of Issuer) Theravance Biopharma, Inc. (Title of Class of Securities) Ordinary Share, $0.00001 Par

TBPH / Theravance Biopharma Inc / Madison Avenue Partners, LP Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. 1)* Theravance Biopharma, Inc. (Name of Issuer) Ordinary Shares, par value $0.00001 per share (Title of Class of Securities) G8807B106 (CUSIP Number) December 31, 202

TBPH / Theravance Biopharma Inc / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Amendment No.

TBPH / Theravance Biopharma Inc / BAUPOST GROUP LLC/MA - NONE Passive Investment

Schedule 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Theravance Biopharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) G8807B106 (CUSIP Number) Calendar Year 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

JOINT FILING AGREEMENT

CUSIP No. G8807B106 SCHEDULE 13G Page 8 of 8 Pages EXHIBIT A JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on this Schedule 13G dated February 11, 2022 (the ?Schedule 13G?), with respect to the Ordinary Share $0.00001 Par Value, of Theravance Biopharma, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securi

TBPH / Theravance Biopharma Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Theravance Biopharma Inc. Title of Class of Securities: Common Stock CUSIP Number: G8807B106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fi

TBPH / Theravance Biopharma Inc / GLAXOSMITHKLINE PLC - AMENDMENT TO FORM SC 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 8)* THERAVANCE BIOPHARMA, INC. (Name of Issuer) Ordinary Shares, par value, $0.00001 (Title of Class of Securities) G8807B106 (CUS

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): January 10, 2022 THERAVANCE BIOPHARMA, INC.

JP Morgan Healthcare Conference January 13, 2022 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain othe

Exhibit 99.1 JP Morgan Healthcare Conference January 13, 2022 THERAVANCE BIOPHARMA ? , THERAVANCE ? , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ? are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. ? 2022 Theravance Biopharma. All rights

THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used her

EX-99.2 3 tm221860d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. © 2022 Theravance Biopharma. All rights rese

Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 17, 2021 THERAVANCE BIOPHARMA, INC.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): December 16, 2021 THERAVANCE BIOPHARMA, INC.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 15, 2021 THERAVANCE BIOPHARMA, INC.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 16, 2021 THERAVANCE BIOPHARMA, INC.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Third Quarter 2021 Financial Results and Business Update November 3, 2021 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in

Exhibit 99.2 Third Quarter 2021 Financial Results and Business Update November 3, 2021 THERAVANCE BIOPHARMA ? , THERAVANCE ? , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ? are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. ? 2021 Therava

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): November 3, 2021 THERAVANCE BIOPHARMA, INC.

Theravance Biopharma, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

Exhibit 99.1 Theravance Biopharma, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update ? Implied 35% share of YUPELRI? (revefenacin) US net sales1: $13.8 million, up 7% from Q3 2020 ? TRELEGY Q3 2021 global net sales: $449 million, up 77% from Q3 20202 ? Restructuring proceeding according to plan DUBLIN, IRELAND ? November 3, 2021 ? Theravance Biopharma, Inc. (?Theravanc

TBPH / Theravance Biopharma Inc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3 )* Theravance Biopharma, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) G8807B106 (CUSIP Number) September 30, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which

CONSULTING AGREEMENT

Exhibit 99.1 CONSULTING AGREEMENT Effective September 30, 2021 (the ?Effective Date?), Bradford J. Shafer (?Consultant?) and Theravance Biopharma US, Inc. (?Theravance Biopharma? or the ?Company?) agree as follows: 1. Services and Payment. Consultant agrees to consult with and advise Theravance Biopharma from time to time, up to five (5) hours per week, at Theravance Biopharma?s request (?Services

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K/A Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 15, 2021 THERAVANCE BIOPHARMA, INC.

TBPH / Theravance Biopharma Inc / Madison Avenue Partners, LP Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* Theravance Biopharma, Inc. (Name of Issuer) Ordinary Shares, par value $0.00001 per share (Title of Class of Securities) G8807B106 (CUSIP Number) September 15, 202

Ampreloxetine Top - line Results from Phase 3 Study (0169) in Patients with Symptomatic Neurogenic Hypotension (nOH) September 15, 2021 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered

Exhibit 99.3 Ampreloxetine Top - line Results from Phase 3 Study (0169) in Patients with Symptomatic Neurogenic Hypotension (nOH) September 15, 2021 THERAVANCE BIOPHARMA ? , THERAVANCE ? , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ? are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used here

A New, Focused Theravance Biopharma September 15, 2021 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certai

Exhibit 99.4 A New, Focused Theravance Biopharma September 15, 2021 THERAVANCE BIOPHARMA ? , THERAVANCE ? , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ? are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. ? 2021 Theravance Biopharma. All

Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension

Exhibit 99.2 Theravance Biopharma, Inc. Announces Top-line Results from a Phase 3 Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension ? Randomized, double-blind, placebo-controlled study did not meet the primary endpoint: improvement in OHSA #1 in patients receiving ampreloxetine for four weeks compared to placebo DUBLIN, IRELAND and SOUTH SAN FRANCISCO, Calif. ?

Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio

Exhibit 99.1 Theravance Biopharma, Inc. Announces Strategic Actions to Focus on Respiratory Disease Portfolio ? Implements significant cost reduction program ? Expects to be sustainably cash flow positive beginning 2H 2022 ? Investor conference call and webcast today at 8:00 AM ET (5:00 AM PT) DUBLIN, IRELAND AND SOUTH SAN FRANCISCO, CALIF. ? SEPTEMBER 15, 2021 ? Theravance Biopharma, Inc. ("Thera

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): September 15, 2021 THERAVANCE BIOPHARMA, INC.

JOINT FILING AGREEMENT

Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi

TBPH / Theravance Biopharma Inc / Point72 Asset Management, L.P. - SCHEDULE 13G Passive Investment

240.13d-102 Schedule 13G - Information to be included in statements filed pursuant to 240.13d-1(b), (c), and (d) and amendments thereto filed pursuant to 240.13d-2. Securities and Exchange Commission, Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.)* (Name of Issuer) Theravance Biopharma, Inc. (Title of Class of Securities) Ordinary Share, $0.00001 Par

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 23, 2021 THERAVANCE BIOPHARMA, INC.

Page 1 of 3

Exhibit 99.1 Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis ? Randomized, double-blind, placebo-controlled study did not meet the primary endpoint: change in the total Mayo score at week eight, relative to placebo ? Izencitinib was well-tolerated and safety data were consistent with expectations fo

Izencitinib (TD - 1473/JNJ - 8398) Oral gut - selective pan - JAK inhibitor to treat inflammatory bowel diseases August 23, 2021 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered tradema

Exhibit 99.2 Izencitinib (TD - 1473/JNJ - 8398) Oral gut - selective pan - JAK inhibitor to treat inflammatory bowel diseases August 23, 2021 THERAVANCE BIOPHARMA ? , THERAVANCE ? , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ? are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Second Quarter 2021 Financial Results and Business Update August 3, 2021 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in t

Exhibit 99.2 Second Quarter 2021 Financial Results and Business Update August 3, 2021 THERAVANCE BIOPHARMA ? , THERAVANCE ? , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ? are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. ? 2021 Theravan

Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

Exhibit 99.1 Theravance Biopharma, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update ? Company reiterates Q3 2021 top-line results timing for ampreloxetine Phase 3 and izencitinib Phase 2b in ulcerative colitis ? Company?s implied 35% share of YUPELRI? (revefenacin) US net sales1: $14.6 million, up 38% from Q2 2020 ? TRELEGY? Q2 2021 global net sales hit $405 million,

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event Reported): August 3, 2021 THERAVANCE BIOPHARMA, INC.

Appendix August 3, 2021 THERAVANCE BIOPHARMA ® , THERAVANCE ® , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ® are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third p

Exhibit 99.3 Appendix August 3, 2021 THERAVANCE BIOPHARMA ? , THERAVANCE ? , the Cross/Star logo and MEDICINES THAT MAKE A DIFFERENCE ? are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries). All third party trademarks used herein are the property of their respective owners. ? 2021 Theravance Biopharma. All rights reserved. Decades - long